Cytokine storm modulation

Cytokine storm modulation refers to the therapeutic intervention aimed at regulating the excessive and uncontrolled release of pro-inflammatory cytokines, a phenomenon known as a cytokine storm or cytokine release syndrome (CRS) [1, 2, 13]. This condition is characterized by systemic hyperinflammation, which can lead to multi-organ failure and death in contexts such as severe viral infections (e.g., COVID-19, influenza), CAR-T cell therapy, and sepsis [8, 10, 15]. Modulation strategies typically target key mediators like Interleukin-6 (IL-6), Interleukin-1 (IL-1), and Tumor Necrosis Factor-alpha (TNF-α), or downstream signaling components like Janus kinases (JAKs) [2, 6, 8]. By dampening this 'storm,' clinicians aim to restore immune homeostasis and prevent tissue damage while ideally maintaining sufficient immune function to clear the underlying trigger [3, 20]. Common pharmacological agents include monoclonal antibodies, small molecule inhibitors, and corticosteroids [5, 7, 8]. Biomarkers such as Interleukin-6, C-reactive protein, and ferritin are frequently used to monitor the severity of the inflammatory response and the efficacy of the modulation [9, 11, 12]. The primary challenge in this approach is achieving a 'Goldilocks' response—suppressing the harmful hyperinflammation without inducing profound immunosuppression that could lead to secondary infections or impaired pathogen clearance [3, 4, 12].

Other names

Cytokine release syndrome modulationCRS modulationHyperinflammation modulationCytokine storm suppressionImmune storm modulation

Modulation is achieved through the antagonism of specific pro-inflammatory cytokines (e.g., IL-6, IL-1β, TNF-α), inhibition of intracellular signaling pathways such as JAK-STAT, or broad immunosuppression using corticosteroids to dampen the systemic inflammatory cascade [1, 2, 8, 14].